Handelsavisen
prelaunch
Companies ›Healthcare ›APRE.O
AP
APRE.O — NASDAQ Biotechnology & Medical Research

Aprea Therapeutics Inc

$0,60
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
7,4M USD
P/E
—
EV / Rev
-62,9x
Div yield
—
Op margin
-827,6 %
ROE
-9,3 %
Net margin
-738,4 %
Debt / equity
0,00
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$0,91
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About

Aprea Therapeutics Inc is a biotechnology company focused on the development of novel therapies for the treatment of rare and life-threatening diseases, primarily in the field of hematology and oncology.

Business. Aprea Therapeutics Inc (APRE.O) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
BUY3 analysts
3 buy0 hold0 sell
Avg 12m price target4,40

Analyst recommendations

3 analysts · consensus Buy
Buy3
Hold0
Sell0
12-month price target
4,40
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
3 analysts · indicative
Ownership→
Geode Capital Management, L.L.C.
largest disclosed fund holder
Profitability→
-9,3 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning APRE.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to APRE.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Aprea Therapeutics Inc (APRE.O) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    Aprea Therapeutics Inc maintains a strong liquidity position, with cash and equivalents amounting to $32.37 million, significantly exceeding its total liabilities of $2.97 million, resulting in a current ratio of 11.15. The company has no long-term debt, and its debt-to-equity ratio is 0.0, indicating a conservative capital structure. The price-to-book ratio of 0.39 and price-to-tangible-book ratio of 0.39 suggest that the company is trading at a substantial discount to its book value, potentially reflecting market skepticism about its near-term profitability.

    The company reported a net loss of $2.81 million and an operating loss of $3.15 million in the latest period, with a return on equity of -9.29% and a return on assets of -8.46%. These metrics indicate that Aprea is not currently generating returns for shareholders and is underperforming relative to the industry's preferred metrics of profitability and capital efficiency. The negative operating and free cash flows (-$3.94 million and -$2.81 million, respectively) further highlight the company's reliance on external financing to fund operations.

    Aprea Therapeutics Inc does not disclose segment or geographic revenue breakdowns in its latest financials, making it difficult to assess the concentration of its revenue streams or geographic exposure. However, as a biotechnology firm, it is likely that its operations are concentrated in the United States, where the majority of its research and development activities are conducted.

    The company's growth trajectory is uncertain, as it has not provided forward-looking revenue guidance. Analysts have assigned a mean price target of $4.40 and a median price target of $5.00, with a mean recommendation of 1.67 (leaning toward "buy"). These estimates suggest that the market sees potential for upside, but the absence of concrete revenue growth projections makes it difficult to assess the company's long-term viability.

    Aprea Therapeutics Inc faces low liquidity and dilution risk, with no immediate filing-based flags detected. The company has a low dilution potential, as the number of basic and diluted shares outstanding is identical, and there is no indication of recent or pending share issuance. However, the company's negative cash flows and lack of profitability could necessitate future equity or debt financing, which may introduce dilution risk.

    There are no recent filings or transcripts provided in the available data to assess Aprea's strategic direction or operational developments. The company's focus on clinical-stage drug development suggests that its future performance will depend on the success of its pipeline and the ability to secure regulatory approvals.

    Key takeaways
    • Aprea Therapeutics Inc has a strong liquidity position with no long-term debt and a current ratio of 11.15.
    • The company is currently unprofitable, with a net loss of $2.81 million and negative returns on equity and assets.
    • The company's valuation is significantly discounted, with a price-to-book ratio of 0.39.
    • Analysts have a generally positive outlook, with a mean price target of $4.40 and a median price target of $5.00.
    • Aprea faces no immediate liquidity or dilution risks, but its long-term viability depends on the success of its drug development pipeline.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-03-16
    Q4 2025 · Quarter highlights
    Open report →

    Revenue $3.3k, −98,4% YoY; Operating income +18,1% YoY.

    Revenue$3.3k−98,4 % YoY
    Operating income-$2.6M+18,1 % YoY
    Net income-$2.5M+15,2 % YoY
    Free cash flow-$2.5M+15,2 % YoY
    EPS—
    Operating cash flow-$12.9M+4,9 % YoY
    Financials
    Income statement
    Revenue$3.3k
    Gross profit—
    Operating income-$2.6M
    Net income-$2.5M
    Margins
    Gross margin—
    Operating margin-79134.4%
    Net margin-73521.9%
    FCF margin-73359.3%
    Balance sheet
    Total assets$15.9M
    Total liabilities$2.8M
    Total equity$13.2M
    Cash & equivalents$14.6M
    Long-term debt$0.00
    Cash flow
    Operating cash flow-$12.9M
    CapEx—
    Free cash flow-$2.5M
    SBC—
    P&L flow · revenue → net income
    Revenue $3.3kOperating costs $2.6MNet income $2.5M
    Highlights
    • ▍Revenue $3.3k, −98,4% YoY
    • ▍Operating income +18,1% YoY
    • ▍Net income +15,2% YoY
    • ▍Free cash flow +15,2% YoY
    • ▍Net margin -73521.9%

    Valuation TTM

    Market price
    $0,60
    Market cap
    $11.7M
    Enterprise valueⓘ
    -$20.7M
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    -62.9x
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    0.4x
    P / Tangible bookⓘ
    0.4x
    Tangible book
    $30.2M
    Net cashⓘ
    $32.4M
    Current ratioⓘ
    11.2
    Debt / equityⓘ
    0.0
    ROAⓘ
    -8.5%
    ROEⓘ
    -9.3%
    Cash conversionⓘ
    140.0%
    CapEx / revenueⓘ
    -2.1%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    -0,72
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    3
    Other metrics
    Revenue
    —
    no estimate
    Segment revenue
    —
    no estimate
    Margin
    —
    no estimate
    Segment margin
    —
    no estimate
    as of 2026-05-16 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPS—no estimate—no estimate-0,72
    Revenue—no estimate—no estimate0 USD
    Operating income—no estimate—no estimate-14,3M USD
    Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution3 analysts
    Strong buy1
    Buy2
    Hold0
    Sell0
    Strong sell0
    12-month price target$4,40 · Median $5,00
    Low $1,20High $7,00
    Operating income · consensus-14,3M USD
    EPS surprise
    −166,8 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$1,20
    Mean$4,40
    Median$5,00
    High$7,00
    Spot$0,60
    +636.2 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin-827,6 %Below median
    Net Margin-738,4 %Below median
    ROE-9,3 %Above median
    Capex / Rev-2,1 %Above median
    D/E0,00Above median
    Cash Conv1,40Above P75

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 634 483 sh10 grants10 insiders
    • BIZZARI JEAN-PIERREDirector · Stock Options (Right to Buy) → Common StockAcquired 12 555 @ $0,73grant · 2026-06-16
    • Seizinger Bernd R.Director · Stock Options (Right to Buy) → Common StockAcquired 12 555 @ $0,73grant · 2026-06-16
    • Grissinger MichaelDirector · Stock Options (Right to Buy) → Common StockAcquired 12 555 @ $0,73grant · 2026-06-16
    • Pamukcu RifatDirector · Stock Options (Right to Buy) → Common StockAcquired 12 555 @ $0,73grant · 2026-06-16
    • Duey MarcDirector · Stock Options (Right to Buy) → Common StockAcquired 12 555 @ $0,73grant · 2026-06-16
    • Gruia GabrielaDirector · Stock Options (Right to Buy) → Common StockAcquired 12 555 @ $0,73grant · 2026-06-16
    • Peters RichardDirector · Stock Options (Right to Buy) → Common StockAcquired 12 555 @ $0,73grant · 2026-06-16
    • HENNEMAN JOHN B IIIDirector · Stock Options (Right to Buy) → Common StockAcquired 12 555 @ $0,73grant · 2026-06-16
    • Peters RichardDirector · Pre-Funded Warrant → Common StockAcquired 123 915 @ $0,00purchase · 2026-03-31
    • Hamill John P.SrVP/CFO/Prin Fin & Acct Ofcr · Pre-Funded Warrant → Common StockAcquired 30 978 @ $0,00purchase · 2026-03-31
    • Hamill John P.SrVP/CFO/Prin Fin & Acct Ofcr · Common Warrant → Common StockAcquired 30 978 @ $0,68purchase · 2026-03-31
    • Peters RichardDirector · Common Warrant → Common StockAcquired 123 915 @ $0,68purchase · 2026-03-31
    • Gilad OrenDirector, President/CEO · Stock Options (Right to Buy) → Common StockAcquired 80 700 @ $0,77grant · 2026-03-12
    • Hamill John P.SrVP/CFO/Prin Fin & Acct Ofcr · Stock Options (Right to Buy) → Common StockAcquired 40 380 @ $0,77grant · 2026-03-12
    • Hamill John P.SrVP/CFO/Prin Fin & Acct Ofcr · Common Warrant → Common StockAcquired 5 700 @ $0,77purchase · 2026-01-30
    • Gilad OrenDirector, President/CEO · Common Warrant → Common StockAcquired 28 100 @ $0,77purchase · 2026-01-30
    • Gilad OrenDirector, President/CEO · Pre-Funded Warrant → Common StockAcquired 21 459 @ $0,00purchase · 2025-12-10
    • Duey MarcDirector · Common Warrant → Common StockAcquired 21 459 @ $1,04purchase · 2025-12-10
    • Hamill John P.SrVP/CFO/Prin Fin & Acct Ofcr · Common Warrant → Common StockAcquired 5 000 @ $1,04purchase · 2025-12-10
    • Gilad OrenDirector, President/CEO · Common Warrants → Common StockAcquired 21 459 @ $1,04purchase · 2025-12-10

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Ev To Revenue
      enterprise_value / revenue
    Source documents
    • Aprea Therapeutics Inc Market data — financials · 2026-05-27
    • Aprea Therapeutics Inc Market data — analyst estimates · 2026-05-27
    • Aprea Therapeutics Inc Market data — ESG · 2026-05-27

    Ownership & reference

    Top holders

    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$0M
    • LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$0M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$0M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M

    Insider activity

    Net buying4 buys · 0 sellsnet $61K10 insiders · last 365d
    • HENNEMAN JOHN B IIIDirector · Common StockOther 3 135 · 2026-06-16
    • Grissinger MichaelDirector · Common StockOther 3 135 · 2026-06-16
    • Gruia GabrielaDirector · Common StockOther 3 135 · 2026-06-16
    • Peters RichardDirector · Common StockOther 3 135 · 2026-06-16
    • BIZZARI JEAN-PIERREDirector · Common StockOther 3 135 · 2026-06-16
    • Duey MarcDirector · Common StockOther 3 135 · 2026-06-16
    • Pamukcu RifatDirector · Common StockOther 3 135 · 2026-06-16
    • Seizinger Bernd R.Director · Common StockOther 3 135 · 2026-06-16
    • Hamill John P.SrVP/CFO/Prin Fin & Acct Ofcr · Common StockOther 10 095 · 2026-03-12
    • Gilad OrenDirector, President/CEO · Common StockOther 20 175 · 2026-03-12
    • Hamill John P.SrVP/CFO/Prin Fin & Acct Ofcr · Common StockBought 5 700 @ $0,89$5K · 2026-01-30
    • Gilad OrenDirector, President/CEO · Common StockBought 28 100 @ $0,89$25K · 2026-01-30
    • Hamill John P.SrVP/CFO/Prin Fin & Acct Ofcr · Common StockBought 5 000 @ $1,17$6K · 2025-12-10
    • Duey MarcDirector · Common StockBought 21 459 @ $1,17$25K · 2025-12-10

    Short positioning

    60.6Kshares short-22.1% vs prior
    1days to cover
    30.9%short of daily vol
    175fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    APRE.OCanonical
    NASDAQ · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 17.9%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 4.9%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): -33.6%Derived (calculated)
    • Return on equity (FY 2025-12-31): -101.3%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): 7.6%Derived (calculated)
    • Return on assets (FY 2025-12-31): -79.1%Derived (calculated)
    • Current ratio (FY 2025-12-31): 5.63xDerived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): 2.8%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -35.6%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 17.9%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -36.1%Derived (calculated)
    • Shares outstanding (annual): 8.19MSEC XBRL filing
    • Total assets (annual): USD 15.93MSEC XBRL filing
    • Current liabilities (annual): USD 2.76MSEC XBRL filing
    • Operating cash flow (annual): USD -12.89MSEC XBRL filing
    • Current assets (annual): USD 15.56MSEC XBRL filing
    • EPS (basic) (annual): USD-PER-SHARES -2SEC XBRL filing
    • Total operating expenses (annual): USD 13.52MSEC XBRL filing
    • EPS (diluted) (annual): USD-PER-SHARES -2SEC XBRL filing
    • Shareholders' equity (annual): USD 12.44MSEC XBRL filing
    • Cash & equivalents (annual): USD 14.6MSEC XBRL filing
    • Operating income (annual): USD -13.23MSEC XBRL filing
    • Net income (annual): USD -12.6MSEC XBRL filing
    • EPS (diluted) (YoY) (2024-12-31 vs 2023-12-31): 40.5%Derived (calculated)
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-07-29 22:34 UTCEVENTHa Price Listing APRE remains DEFICIENT (NASDAQ) — cure period. closed below $1.00 for 30 consecutive trading days (last close $0.741). cure deadline 2027-01-17 (172 days remaining).
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-17FILINGFORM 8-K →
    2026-06-16 00:00 UTCINSIDER16 insider transactions — 2026-06 8 derivative
    2026-06-16INSIDERHENNEMAN JOHN B III transacted 3.1k sh — Director
    2026-06-16INSIDERGrissinger Michael transacted 3.1k sh — Director
    2026-06-16INSIDERGruia Gabriela transacted 3.1k sh — Director
    2026-06-16INSIDERPeters Richard transacted 3.1k sh — Director
    2026-06-16INSIDERBIZZARI JEAN-PIERRE transacted 3.1k sh — Director
    2026-06-16INSIDERDuey Marc transacted 3.1k sh — Director
    2026-06-16INSIDERPamukcu Rifat transacted 3.1k sh — Director
    2026-06-16INSIDERSeizinger Bernd R. transacted 3.1k sh — Director
    2026-06-16INSIDERPamukcu Rifat acquired 12.6k sh Stock Options (Right to Buy) — Director
    2026-06-16INSIDERGrissinger Michael acquired 12.6k sh Stock Options (Right to Buy) — Director
    2026-06-16INSIDERGruia Gabriela acquired 12.6k sh Stock Options (Right to Buy) — Director
    2026-06-16INSIDERPeters Richard acquired 12.6k sh Stock Options (Right to Buy) — Director
    2026-06-16INSIDERHENNEMAN JOHN B III acquired 12.6k sh Stock Options (Right to Buy) — Director
    2026-06-16INSIDERBIZZARI JEAN-PIERRE acquired 12.6k sh Stock Options (Right to Buy) — Director
    2026-06-16INSIDERDuey Marc acquired 12.6k sh Stock Options (Right to Buy) — Director
    2026-06-16INSIDERSeizinger Bernd R. acquired 12.6k sh Stock Options (Right to Buy) — Director
    2026-05-15FILING424B7 filing →
    2026-05-13FILING10-Q filing →
    2026-05-13FILING8-K filing →
    2026-04-30FILINGDEF 14A filing →
    2026-04-29FILING424B3 filing →
    2026-04-01FILING8-K filing →
    2026-03-31 00:00 UTCINSIDER8 insider transactions — 2026-03 6 derivative
    2026-03-31INSIDERPeters Richard acquired 123.9k sh Pre-Funded Warrant — Director
    2026-03-31INSIDERHamill John P. acquired 31.0k sh Pre-Funded Warrant — SrVP/CFO/Prin Fin & Acct Ofcr
    2026-03-30FILINGFORM 8-K →
    2026-03-19FILING424B3 filing →
    2026-03-16 08:00 UTCEARNINGSQuarterly results — Q4 2025 Revenue USD 0.0M · Net USD -2.5M
    2026-03-16 08:00 UTCEARNINGSAnnual results — FY 2026 Revenue USD 0.3M · Net USD -12.6M
    2026-03-16FILING10-K filing →
    2026-03-16FILING8-K filing →
    2026-03-12INSIDERHamill John P. transacted 10.1k sh — SrVP/CFO/Prin Fin & Acct Ofcr
    2026-03-12INSIDERGilad Oren transacted 20.2k sh — Director, President/CEO
    2026-03-12INSIDERGilad Oren acquired 80.7k sh Stock Options (Right to Buy) — Director, President/CEO
    2026-03-12INSIDERHamill John P. acquired 40.4k sh Stock Options (Right to Buy) — SrVP/CFO/Prin Fin & Acct Ofcr
    Showing the 40 most recent of 63 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage